Targeting CLPTM1L for treatment and prevention of cancer

Patent metadata

Field	Value
Publication number	US-10829548-B2
Application number	US-201916289023-A
Country	US
Kind code	B2
Filing date	Feb 28, 2019
Priority date	Jan 14, 2014
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

Provided herein are therapeutic agents having specificity for human CLPTM1L polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L protein dysfunction (e.g., pathogenic production, modification, or function).

First claim

We claim:

1. A method for treating a tumor or cancer comprising administering to a human subject in need thereof a therapeutically effective amount of a compound comprising a CLPTM1L-targeting agent, wherein the CLPTM1L-targeting agent is a monoclonal antibody specific for at least a portion of a CLPTM1L polypeptide and selected from anti-CLPTM1L monoclonal antibody clones 6-1 (ATCC PTA-125531), 10-2 (ATCC PTA-125532), and 10-3 (ATCC PTA-125530), wherein the tumor or cancer is selected from the group consisting of pancreatic cancer, melanoma, bladder cancer, kidney cancer, ovarian cancer, colon cancer, colorectal cancer, breast cancer, carcinoma, and stomach cancer, whereby the tumor or cancer is treated in the subject.

2. The method of claim 1 , wherein the tumor exhibits resistance to a chemotherapeutic agent.

3. The method of claim 2 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, gemcitabine, carboplatin, carmustine, methotrexate, fluorouracil, goserelin, leuprolide, tamoxifen, docetaxel, paclitaxel, aldesleukin, interleukin-2, etoposide (VP-16), interferon-alpha, tretinoin (ATRA), bleomycin, dactinomycin, daunorubicin, doxorubicin, mitomycin, vinblastine, and vincristine.

4. The method of claim 1 , wherein the compound is administered with a pharmaceutically acceptable carrier.

Assignees

• Medical College Wisconsin Inc

Inventors

• James Michael A

Classifications

• A61P11/00 Primary

  Drugs for disorders of the respiratory system · CPC title

• C07K16/3015

  Breast · CPC title

• C07K16/3038

  Kidney, bladder · CPC title

• C07K16/3023

  Lung · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title